Search research articles
Contact Us
Filters
Showing results (1-10 of 161) with videos related to
Page
of 17
Sort By:
The Breast Journal
|
February 1, 2003
Capecitabine and PPE syndrome: a case report
Patricia M LoRusso
Seminars in Oncology
|
March 20, 2003
Phase I studies of ZD1839 in patients with common solid tumors
Patricia M Lorusso
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trials: an answer to drug development stagnation?
Patricia M LoRusso
Journal of the National Cancer Institute
|
November 30, 2022
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials
Patricia M LoRusso, Boris Freidlin
Clinical Breast Cancer
|
December 1, 2010
The role of phosphoinositide 3-kinase in breast cancer: an overview
Patricia M LoRusso, Scott A Boerner
Expert Opinion on Investigational Drugs
|
June 14, 2008
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
Patricia M Lorusso, Joseph Paul Eder
Mayo Clinic Proceedings
|
October 7, 2017
Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer
Mitesh J Borad, Patricia M LoRusso
Future Oncology (London, England)
|
December 8, 2017
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Deborah B Doroshow, Patricia M LoRusso
The New England Journal of Medicine
|
September 21, 2020
One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable
Patricia M LoRusso, Judith S Sebolt-Leopold
Pigment Cell & Melanoma Research
|
November 10, 2019
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
Patricia M LoRusso, Kurt Schalper, Jeffrey Sosman
Page
of 17
Search research articles
Search
Showing results (1-10 of 161) with videos related to
Sort By:
Page
of 17
The Breast Journal
|
February 1, 2003
Capecitabine and PPE syndrome: a case report
Patricia M LoRusso
Seminars in Oncology
|
March 20, 2003
Phase I studies of ZD1839 in patients with common solid tumors
Patricia M Lorusso
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trials: an answer to drug development stagnation?
Patricia M LoRusso
Journal of the National Cancer Institute
|
November 30, 2022
Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials
Patricia M LoRusso, Boris Freidlin
Clinical Breast Cancer
|
December 1, 2010
The role of phosphoinositide 3-kinase in breast cancer: an overview
Patricia M LoRusso, Scott A Boerner
Expert Opinion on Investigational Drugs
|
June 14, 2008
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
Patricia M Lorusso, Joseph Paul Eder
Mayo Clinic Proceedings
|
October 7, 2017
Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer
Mitesh J Borad, Patricia M LoRusso
Future Oncology (London, England)
|
December 8, 2017
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Deborah B Doroshow, Patricia M LoRusso
The New England Journal of Medicine
|
September 21, 2020
One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable
Patricia M LoRusso, Judith S Sebolt-Leopold
Pigment Cell & Melanoma Research
|
November 10, 2019
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
Patricia M LoRusso, Kurt Schalper, Jeffrey Sosman
Page
of 17